Scarica l'app Stockscreener
1.935
0.77%
-0.015
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché BMEA Giù?
Forum
Previsione
Precedente Chiudi:
$1.95
Aprire:
$1.97
Volume 24 ore:
892.36K
Relative Volume:
0.65
Capitalizzazione di mercato:
$139.54M
Reddito:
-
Utile/perdita netta:
$-61.80M
Rapporto P/E:
-1.2733
EPS:
-1.5197
Flusso di cassa netto:
$-70.37M
1 W Prestazione:
+9.94%
1M Prestazione:
+42.28%
6M Prestazione:
+17.27%
1 anno Prestazione:
+11.85%
Intervallo 1D:
$1.86
$1.99
Intervallo di 1 settimana:
$1.68
$1.99
Portata 52W:
$0.8719
$3.08
Biomea Fusion Inc Stock (BMEA) Company Profile
Nome
Biomea Fusion Inc
Settore
Industria
Telefono
(650) 980-9099
Indirizzo
1599 INDUSTRIAL ROAD, SAN CARLOS
Compare BMEA vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
BMEA
Biomea Fusion Inc
|
1.93 | 140.98M | 0 | -61.80M | -70.37M | -1.5197 |
VRTX
Vertex Pharmaceuticals Inc
|
442.54 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
748.28 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
841.84 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
335.34 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
317.06 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Biomea Fusion Inc Stock (BMEA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-13 | Iniziato | Rodman & Renshaw | Buy |
| 2025-08-28 | Iniziato | Jefferies | Buy |
| 2025-06-03 | Ripresa | Piper Sandler | Overweight |
| 2024-10-09 | Iniziato | Edward Jones | Buy |
| 2024-09-27 | Aggiornamento | Rodman & Renshaw | Neutral → Buy |
| 2024-09-27 | Aggiornamento | Truist | Hold → Buy |
| 2024-08-29 | Iniziato | CapitalOne | Overweight |
| 2024-06-11 | Downgrade | Truist | Buy → Hold |
| 2024-06-07 | Downgrade | Barclays | Overweight → Equal Weight |
| 2024-04-02 | Downgrade | JP Morgan | Overweight → Neutral |
| 2024-02-06 | Iniziato | Truist | Buy |
| 2023-07-27 | Iniziato | Scotiabank | Sector Outperform |
| 2023-06-26 | Downgrade | Jefferies | Buy → Hold |
| 2023-05-12 | Iniziato | Barclays | Overweight |
| 2023-03-29 | Reiterato | Oppenheimer | Outperform |
| 2023-03-28 | Reiterato | H.C. Wainwright | Buy |
| 2023-02-24 | Iniziato | Citigroup | Buy |
| 2022-06-02 | Ripresa | H.C. Wainwright | Buy |
| 2022-01-12 | Iniziato | H.C. Wainwright | Buy |
| 2021-12-17 | Iniziato | Oppenheimer | Outperform |
| 2021-05-11 | Iniziato | JP Morgan | Overweight |
| 2021-05-11 | Iniziato | Jefferies | Buy |
| 2021-05-11 | Iniziato | Piper Sandler | Overweight |
Mostra tutto
Biomea Fusion Inc Borsa (BMEA) Ultime notizie
BMEA.O PE Ratio & Valuation, Is BMEA.O Overvalued - Intellectia AI
COVALENT-212 study enrolls participants for icovamenib diabetes research, Biomea Fusion initiates - Traders Union
Biomea Fusion warns diabetes remains poorly controlled despite standard therapies - Traders Union
BMEA Forecast, Price Target & Analyst Ratings | BIOMEA FUSION INC (NASDAQ:BMEA) - ChartMill
Biomea Fusion Advances Phase 2 Add-On Therapy Trial in Ozempic-Treated Diabetes - TipRanks
BMEA: Analyst Rating Maintained at Buy with Price Target Unchanged | BMEA Stock News - GuruFocus
Biomea Fusion, Inc. (NASDAQ:BMEA) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Biomea Fusion (BMEA) awards 452,512 stock options to director and officer Erdtmann - Stock Titan
Biomea Fusion (BMEA) interim CEO awarded 667,477 options at $1.49 strike - Stock Titan
Icovamenib development timeline includes Phase II updates and 52-week data in 2026 - Traders Union
BMEA Technical Analysis & Stock Price Forecast - Intellectia AI
Biomea Fusion Announces First Patient Dosed in Newly Initiated Phase II Programs Enrolling Type 2 Diabetes Patients Failing on Standard-of-Care Therapies - The Manila Times
Biomea Fusion Announces First Patient Dosed in Newly - GlobeNewswire
Biomea Fusion Details Icovamenib Diabetes Milestones, Teases BMF-650 Obesity Readouts - MarketBeat
Biomea Fusion Teases Q2 Phase 1 Data for Oral GLP-1 BMF-650, Advances Icovamenib in Diabetes - MarketBeat
Biomea Fusion reports 24 percent jump in insulin secretion in Phase 2 Icovamenib study - Traders Union
Analysts sentiment on Biomea Fusion (BMEA) remains strong amid strong diabetes trial results - MSN
Is Biomea Fusion Inc stock a good pick for beginners2026 PostEarnings & Weekly High Return Stock Forecasts - baoquankhu1.vn
Biomea Fusion (NASDAQ:BMEA) Upgraded by Wall Street Zen to Hold Rating - MarketBeat
Biomea Fusion (NASDAQ:BMEA) Price Target Raised to $7.00 at Citigroup - MarketBeat
HC Wainwright Comments on Biomea Fusion Q1 Earnings - MarketBeat
Can Biomea Fusion (NASDAQ:BMEA) Afford To Invest In Growth? - Yahoo Finance
Biomea Fusion prioritizes key data delivery for clinical programs - Traders Union
Biomea Fusion Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Piper Sandler Maintains Biomea Fusion(BMEA.US) With Buy Rating, Cuts Target Price to $6 - Moomoo
Analysts Sentiment on Biomea Fusion (BMEA) Remains Strong Amid Strong Diabetes Trial Results - Insider Monkey
Biomea Fusion 2025 Financial Report - AlphaStreet
Biomea Fusion's (BMEA) Buy Rating Reaffirmed at D. Boral Capital - MarketBeat
Biomea Fusion, Inc. 2025 Annual Report: Advancing Oral Diabetes & Obesity Therapies with Innovative Small Molecule Drugs - Minichart
Aug Shorts: Can Biomea Fusion Inc ride the EV wave2026 Price Swings & Reliable Trade Execution Plans - baoquankhu1.vn
Biomea Fusion Reports Full Year 2025 Financial Results and Corporate Highlights - Bitget
Biomea Fusion (NASDAQ:BMEA) Issues Earnings Results - MarketBeat
Biomea 10-K: $0 Revenue, $(1.18) EPS; net loss narrows to $(61.80)M - TradingView
BMEA: Clinical progress in diabetes and obesity, reduced net loss, and strong cash position into 2027 - TradingView
Biomea Fusion (NASDAQ: BMEA) highlights icovamenib Phase II data - Stock Titan
Biomea Fusion, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Biomea Fusion (BMEA) cuts 2025 loss as icovamenib and GLP‑1 obesity programs advance - Stock Titan
Biomea Fusion targets new partnerships and investor interest at BIOEurope2026 - Traders Union
Biomea Fusion, Inc. Auditor Raises 'Going Concern' Doubt - marketscreener.com
Biomea Fusion (BMEA) Expected to Announce Quarterly Earnings on Monday - MarketBeat
If You Invested $1,000 in Biomea Fusion, Inc. (BMEA) - Stock Titan
BMEA SEC FilingsBiomea Fusion, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Street Watch: Is Biomea Fusion Inc stock overvalued or fairly priced2026 Closing Moves & Verified Momentum Stock Watchlist - baoquankhu1.vn
Heights Capital Management Inc. Reduces Stock Holdings in Biomea Fusion, Inc. $BMEA - MarketBeat
Why Is Biomea Fusion (BMEA) Stock Down 63% Today? - TradingView
Biomea Fusion, Inc. (BMEA) Presents at 19th International Conference on Advanced Technologies & Treatments for Diabetes 2026Slideshow (NASDAQ:BMEA) 2026-03-16 - Seeking Alpha
Biomea Fusion Presents Positive Phase II COVALENT-111 Data in Type 2 Diabetes - National Today
Juan Pablo Frias presents diabetes research for Biomea Fusion at ATTD 2026 - Traders Union
Biomea Fusion Reports Positive Phase II Data For Diabetes Drug Icovamenib - Benzinga
Biomea Fusion Presents Phase II COVALENT-111 Data in Type 2 Diabetes at the 19th International Conference on Advanced Technologies & Treatments for Diabetes 2026 - The Manila Times
Biomea Fusion Reports Positive 52-Week Results for Icovamenib in Type 2 Diabetes at ATTD 2026 Conference - Quiver Quantitative
Biomea Fusion Inc Azioni (BMEA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Biomea Fusion Inc Azioni (BMEA) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Hitchcock Michael J.M. | Interim CEO |
Dec 02 '25 |
Buy |
0.99 |
100,000 |
99,180 |
115,000 |
| Erdtmann Rainer M | See Remarks |
Nov 28 '25 |
Buy |
1.10 |
40,000 |
44,052 |
683,027 |
| Erdtmann Rainer M | See Remarks |
Dec 01 '25 |
Buy |
1.05 |
10,000 |
10,500 |
693,027 |
2.68%
0.34%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):